Our Company

FDA IND approval for Phase 2 clinical trial in progressive supranuclear palsy(US)

Orphan Drug Designation for Progressive Supranuclear Palsy (KR)

Completed patient recruitment in global Phase 2 clinical trial for Alzheimer's disease (US, EU)

Topline Results Announced for Phase 2 Clinical Trial in Progressive Supranuclear Palsy (KR)

IND Approval for Phase 2 Clinical Trial in Progressive Supranuclear Palsy (KR)

European IND approval for Phase 2 clinical trial in Alzheimer's disease (7 EU countries)

Signed a domestic license agreement with Samsung Pharmaceuticals to develop a treatment for Alzheimer's disease

Phase 3 BPH Study Results Announced (KR)

IND approval for clinical extension of Phase 2 trial in progressive supranuclear palsy (KR)

IND approval for Phase 3 clinical trial in Alzheimer's disease (KR)

Launch of global Phase 2 clinical trial in Alzheimer's disease (US)

FDA IND approval for Phase 2 clinical trial in Alzheimer's disease (US)

Alzheimer's Disease Phase 2 Clinical Trial Results Announced (KR)

Phase 3 pancreatic cancer trial results announced (KR)

TeloVac Phase 3 Clinical Trial in Pancreatic Cancer Results Announced (UK)

Signed a management transfer agreement with Samsung Pharma (incorporated as an affiliated company)

Conditional Marketing Authorization for RIAVAX® for pancreatic cancer immuno-oncology (KR)

IND approval for Phase 3 clinical trial in pancreatic cancer (KR)

Signed a domestic license agreement with Samsung Pharma for RIAVAX® in Korea

Phase 2 BPH Study Results Announced (KR)

Create a company

Listing on the KOSDAQ market

Acquisition of GemVax AS

Teloid Arguments